EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis

Bing Zhuang, Liangying Gan, Bin Liu, Weijie Yuan, Ming Shi, Ai Peng iD, Lihua Wang, Xiaolan Chen, Tongqiang Liu, Shiying Zhang, Song Wang iD, Qing Gao und 19 weitere

Nephrology Dialysis Transplantation · 27.09.2024 · 39 (10) · 1649-1661

DOI: 10.1093/ndt/gfae053 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.03.2024. Verfasst von Bing Zhuang und 30 weiteren Autor:innen. Beteiligte Einrichtung: Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Renal Dialysis, Hyperphosphatemia, Chelating Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Shanghai Alebund Pharmaceuticals Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

VS-505 (AP301), an acacia and ferric oxyhydroxide polymer, is a novel fiber-iron-based phosphate binder. This two-part Phase 2 study evaluated the tolerability, safety and efficacy of oral VS-505 administered three times daily with meals in treating hyperphosphatemia in chronic kidney disease (CKD) patients receiving maintenance hemodialysis (MHD).

Methods

In Part 1, patients received dose-escalated treatment with VS-505 2.25, 4.50 and 9.00 g/day for 2 weeks each, guided by serum phosphorus levels. In Part 2, patients received randomized, open-label, fixed-dosage treatment with VS-505 (1.50, 2.25, 4.50 or 6.75 g/day) or sevelamer carbonate 4.80 g/day for 6 weeks. The primary efficacy endpoint was the change in serum phosphorus.

Results

The study enrolled 158 patients (Part 1: 25; Part 2: 133), with 130 exposed to VS-505 in total. VS-505 was well tolerated. The most common adverse events were gastrointestinal disorders, mainly feces discolored (56%) and diarrhea (15%; generally during Weeks 1–2 of treatment). Most gastrointestinal disorders resolved without intervention, and none was serious. In Part 1, serum phosphorus significantly improved (mean change −2.0 mg/dL; 95% confidence interval −2.7, −1.4) after VS-505 dose escalation. In Part 2, serum phosphorus significantly and dose-dependently improved in all VS-505 arms, with clinically meaningful reductions with VS-505 4.50 and 6.75 g/day, and sevelamer carbonate 4.80 g/day [mean change −1.6 (−2.2, −1.0), −1.8 (−2.4, −1.2) and −1.4 (−2.2, −0.5) mg/dL, respectively]. In both parts, serum phosphorus reductions occurred within 1 week of VS-505 initiation, returning to baseline within 2 weeks of VS-505 discontinuation.

Conclusion

VS-505, a novel phosphate binder, was well tolerated with a manageable safety profile, and effectively and dose-dependently reduced serum phosphorus in CKD patients with hyperphosphatemia receiving MHD. Clinical Trial registration number NCT04551300

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisHyperphosphatemiaChelating AgentsHumansMaleFemaleMiddle AgedAgedDose-Response Relationship, DrugAdultPhosphatesFerric CompoundsSevelamerFollow-Up StudiesKidney Failure, ChronicRenal Insufficiency, Chronic

Stichwörter der Autor:innen

VS-505clinical studyhemodialysishyperphosphatemiaphosphate binder

Substanzen

Chelating AgentsPhosphatesFerric CompoundsSevelamer

Autor:innen und Institutionen

  • Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.
  • Department of Nephrology, Peking University People's Hospital, Beijing, China.
  • Nephrology Department, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.
  • Nephrology Department, Shanghai General Hospital, Shanghai, China.
  • Nephrology Department, Renmin Hospital of Wuhan University, Wuhan, China.
  • Nephrology Department, Shanghai Tenth Hospital, Shanghai, China.

ORCID-Profile: Ai Peng, Song Wang

Förderung

  • Shanghai Alebund Pharmaceuticals Limited

Zitieren

APA

Zhuang, B., Gan, L., Liu, B., Yuan, W., Shi, M., Peng, A., Wang, L., Chen, X., Liu, T., Zhang, S., Wang, S., Gao, Q., Wang, B., Zheng, H., Liu, C., Luo, Y., Ye, H., Lin, H., Li, Y., …, & Zuo, L. (2024). Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis. Nephrology Dialysis Transplantation, 39(10), 1649-1661. https://doi.org/10.1093/ndt/gfae053

Vancouver

Zhuang B, Gan L, Liu B, Yuan W, Shi M, Peng A, et al. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis. Nephrology Dialysis Transplantation. 2024;39(10):1649-1661. doi:10.1093/ndt/gfae053

BibTeX
@article{Zhuang2024,
  author = {Zhuang, Bing and Gan, Liangying and Liu, Bin and Yuan, Weijie and Shi, Ming and Peng, Ai and Wang, Lihua and Chen, Xiaolan and Liu, Tongqiang and Zhang, Shiying and Wang, Song and Gao, Qing and Wang, Baoxing and Zheng, Huixiao and Liu, Changhua and Luo, Yuan and Ye, Hong and Lin, Hongli and Li, Yiwen and He, Qiang and Zheng, Feng and Luo, Ping and Long, Gang and Lu, Wei and Li, Kanghui and Yang, Junwei and Liu, Yingxue Cathy and Zhang, Zhizheng and Li, Xiaoling and Zhang, Weifeng and Zuo, Li},
  title = {Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {10},
  pages = {1649--1661},
  doi = {10.1093/ndt/gfae053}
}
Kostenlos starten →